Background: Several studies have demonstrated harm associated with using erythropoiesis-stimulating agents (ESA) to achieve higher hemoglobin (Hb) levels. Subsequently, more conservative use of ESAs has changed anemia therapy in patients with chronic renal failure.
Objective: The objectives were to identify transfusion rates in hemodialysis (HD) patients during the first year of therapy, to identify factors associated with the probability of transfusion, describe reasons for the transfusions, and identify the Hb values associated with each transfusion. An exploratory objective was to describe the age of red blood cell transfusions.
Design: This was a multicenter prospective observational cohort study.
Setting: There were 12 study sites in 5 Canadian provinces. The study was performed from 2012 to 2014.
Methods: The study patients were adult incident chronic HD patients in these centers. Patients with acute kidney injury, peritoneal dialysis, and planned transfer to satellite units were excluded. Patients had to receive at least 1 month of chronic HD to be eligible. Data for 3 months prior to HD were obtained by retrospective chart review. Prospectively, charts were reviewed monthly for 12 months for data abstraction.
Results: There were 314 patients enrolled and 79.9% completed 12 month follow-up. Ninety-four (29.9%) patients received at least 1 unit of blood. During the first 90 days, the transfusion episode rate was 148.4 per 100 patient-years compared with 62.6 per 100 patient-years post 90 days. The most frequent indication was a low Hb value (92%) with gastrointestinal bleeding, surgical blood loss, and fatigue accounting for 9.9%, 8.6%, and 4.5%, respectively. Some patients had >1 indication. The mean Hb values prior to transfusion episodes ranged from 75.3 to 78.6 g/L. Cox regression analysis on time to first transfusion and time to first hospitalization/death both showed an association with inpatient initiation of HD. Some 37.5% initiated HD as an inpatient and differed from those starting as an outpatient. They had less predialysis care and laboratory data suggested more inflammation. The mean and median ages of the blood units transfused were 24.9 (SD = 10.0) and 23 days (interquartile range = 17-33).
Conclusions: This work reported the blood transfusion rate in incident HD patients in Canada during a period associated with conservative ESA prescription. The major indication for transfusion was a low Hb rather than clinical symptoms. Initiation of HD as an inpatient was independently associated with the probability of receiving a blood transfusion. These findings require further investigation.
Keywords: erythropoiesis-stimulating agent; hemodialysis; transfusion.
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christine M. Ribic has received research grants from Astellas, Leo, Pfizer, and Amgen and is a consultant to Astellas, Leo, Pfizer, and Alexion. Serge H. Cournoyer has received research grants from Amgen, Rockwell, Bayer, GSK, and Abbvie. He is a consultant to Amgen, Sanofi, and Otsuka and is a member of the speaker’s bureau for Otsuka. Melanie Poulin-Costello is a former employee of Amgen Inc and has stock in Amgen Inc. David N. Churchill is a consultant to Amgen, Capsule Communication, and Indegene and owns stock in Amgen, Baxter, and Pfizer. Norman Muirhead has received research grants from Janssen, Amgen, Pfizer, GSK, and BMS. The remaining authors have no conflicts of interest to declare.
2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney DiseaseY Tsubakihara et al. Ther Apher Dial 14 (3), 240-75. PMID 20609178.The Japanese Society for Dialysis Therapy (JSDT) guideline committee, chaired by Dr Y. Tsubakihara, presents the Japanese guidelines entitled "Guidelines for Renal Anemia …
[REIN Report 2011--summary]C Couchoud et al. Nephrol Ther 9 Suppl 1, S3-6. PMID 24119584.Access to the waiting list is evaluated on a cohort of 51,846 new patients who started dialysis between 2002 and 2011 in 25 regions. The probability of first wait-listing …
Transfusion Burden in Non-Dialysis Chronic Kidney Disease Patients With Persistent Anemia Treated in Routine Clinical Practice: A Retrospective Observational StudyKM Fox et al. BMC Nephrol 13, 5. PMID 22273400.Transfusions were prevalent and the trigger hemoglobin concentration was approximately 9 g/dL among ND-CKD patients with anemia. To reduce the transfusion burden, clinici …
Trends in Anemia Management Practices in Patients Receiving Hemodialysis and Peritoneal Dialysis: A Retrospective Cohort AnalysisJB Wetmore et al. Am J Nephrol 41 (4-5), 354-61. PMID 26107376.In patients receiving persistent dialysis, dose and frequency of ESA administrations decreased during the period 2007-2011. Mean hemoglobin levels decreased by more than …
Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease [Internet]M Chung et al. PMID 23230575. - ReviewCombining the evidence addressing Key Questions 2, 3, and 4, we can conclude that all currently available laboratory biomarkers of iron status (either newer or classical …
Cited by 1 PubMed Central articles
Risk of Iron Overload With Chronic Indiscriminate Use of Intravenous Iron Products in ESRD and IBD PopulationsG Rostoker et al. Heliyon 5 (7), e02045. PMID 31338466. - ReviewThe routine use of recombinant erythropoiesis-stimulating agents (ESA) over the past three decades has enabled the partial correction of anaemia in most patients with end …
- Churchill DN, Taylor DW, Cook RJ, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992;19:214-234. - PubMed
- Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. - PubMed
- Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032. - PubMed
- McMurray JJV, Parfrey PS, Adamson JW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int suppl. 2012;2:279-335.